CNS has a diverse and expanding pipeline of oncological solutions for GBM
Novel Additions to a Proven and Trusted Class of Medicines
There have been no major additions to the treatment options for newly diagnosed GBM patients since 2005. We are working to change that.
Our lead product candidate, TPI 287, is a late-stage, novel, blood brain barrier permeable taxane-derivative (abeotaxane) in development for the treatment of Glioblastoma Multiforme (GBM). TPI 287 has been studied in over 350 patients to date, including clinical trials as monotherapy and combination with bevacizumab.
A Focused and Targeted CNS Oncology Pipeline
TPI 287
Sponsor: CNSP
Indication: Glioblastoma Multiforme (GBM)
Research
100% Complete
Preclincal
100% Complete
Phase 1
100% Complete
Phase 2
0% Complete
Potentially Pivotal
A Much Bigger Story Beyond GBM
15,000 Patients
Primary Brain Tumors
6,000 Patients
High Grade Gliomas in Pediatrics
45,000 Patients
Brain Metastases - Combo with Radiation Therapy
1,200 Patients
Primary CNS Lymphoma (PCNSL)